A Nagita, M Ando – 30 December 2003 – No published reports compare hepatic α‐tocopherol (adjusted for hepatic lipid content) with indicators of blood α‐tocopherol in adult patients with various liver diseases. α‐Tocopherol was simultaneously measured in liver biopsy tissues and blood from 66 subjects (9 comparison patients hospitalized for biliary tract surgery, 13 with chronic persistent hepatitis, 9 with chronic aggressive hepatitis, 10 with acute hepatitis, 10 with cirrhosis, 7 with both cirrhosis and hepatic cell carcinoma, and 8 with fatty liver).

T Bizollon, U Palazzo, C Ducerf, M Chevallier, M Elliott, J Baulieux, M Pouyet, C Trepo – 30 December 2003 – Recurrent hepatitis C virus (HCV) in liver transplant patients is a major cause of graft loss, liver failure, and need for retransplantation. The results available to date with the use of interferon alfa (IFN‐α) in the treatment of recurrent HCV in liver transplant patients have been disappointing.

F Donato, A Tagger, R Chiesa, M L Ribero, V Tomasoni, M Fasola, U Gelatti, G Portera, P Boffetta, G Nardi – 30 December 2003 – We performed a case‐control study to assess the association of hepatocellular carcinoma (HCC) with hepatitis B virus (HBV) and hepatitis C virus (HCV) infection and alcohol drinking.

I Ogata, A S Auster, A Matsui, P Greenwel, A Geerts, T D'Amico, K Fujiwara, E Kessler, M Rojkind – 30 December 2003 – Using a polyclonal antibody raised against a liver stellate cell (LSC) line derived from a rat CCl4‐cirrhotic liver, we isolated 14 clones from a complementary DNA library prepared with total RNA extracted from the same cell line, with nucleotide sequences homologous to that of the type I procollagen C‐proteinase enhancer protein (PCPE) gene. The longest PCPE insert of 1,530 base pairs contained an open reading frame coding for 468 amino acids.

G Boigk, L Stroedter, H Herbst, J Waldschmidt, E O Riecken, D Schuppan – 30 December 2003 – Silymarin (SIL), a standardized plant extract containing about 60% polyphenole silibinin, is used as a hepatoprotective agent. Its antifibrotic potential in chronic liver diseases has not been explored. Therefore, we applied SIL to adult Wistar rats that were subjected to complete bile duct occlusion (BDO) by injection of sodium amidotrizoate (Ethibloc). This treatment induces progressive portal fibrosis without significant inflammation.

N Omori, M Omori, R P Evarts, T Teramoto, M J Miller, T N Hoang, S S Thorgeirsson – 30 December 2003 – The sialomucin CD34 is expressed on human and mouse hematopoietic stem cells and is used as an important marker for isolating the hematopoietic stem/progenitor cells. The involvement of hepatic stem cells in liver regeneration under certain conditions in adult rats is now well supported. The objective of the present research was to explore the idea that CD34 might also be expressed on hepatic stem cell progeny.

M P Manns, P Obermayer‐Straub – 30 December 2003 – Enzymes of phase I (cytochromes P450) and phase II (UDP [uridine diphosphate]‐glucuronosyltransferases) of drug metabolism are targets of autoimmunity in the following chronic liver diseases of different etiology: 1)autoimmune hepatitis (AIH); 2) hepatitis associated with the autoimmune polyendocrine syndrome type 1 (APS‐1); 3) virus‐induced autoimmunity; and 4) drug‐induced hepatitis.

R Romeo, M G Rumi, N i Del, M Colombo – 30 December 2003

H Harada, H Imamura, S Miyagawa, S Kawasaki – 30 December 2003 – The favorable therapeutic effect of preoperative portal vein embolization (PVE) was analyzed by assessing various volumetric, cell kinetic and morphometric parameters and examining histologically the embolized and nonembolized lobes of 15 patients who underwent extended right lobectomy 2 to 3 weeks after PVE.

N Aiba, M J McGarvey, J Waters, S J Hadziyannis, H C Thomas, P Karayiannis – 30 December 2003 – The cellular localization of the precore/core and core proteins was studied by immunofluorescence following transfection of 143 thymidine kinase‐negative (TK‐) and Hep‐G2 cells with expression constructs containing wild‐type (hepatitis B e antigen [HBeAg]‐positive) and precore mutant (HBeAg‐negative) sequences. Precore/core constructs with the wild‐type phenotype result in strong nuclear staining, while, in contrast, constructs expressing core antigen alone have strong cytoplasmic staining.